换一批
换一批Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
第一作者：
Ravi,Salgia
第一单位：
Authors' Affiliations: Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois; Genentech, Inc., South San Francisco, California; and Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey.
作者：
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);女(雌)性(Female);人类(Humans);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);肿瘤(Neoplasms)
DOI
10.1158/1078-0432.CCR-13-2070
PMID
24493831
发布时间
2021-10-21
- 浏览18
Clinical cancer research
1666-75页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
